NDAINTRAVENOUSPOWDERPriority Review
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
EMBLAVEO (aztreonam and avibactam) by AbbVie is beta lactamase inhibitors [moa]. Approved for older, no alternative options for the treatment of complicated intra-abdominal infections (ciai) including those caused by the following susceptible gram-negative microorganisms: escherichia coli, klebsiella pneumoniae and 4 more indications. First approved in 2025.
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMBLAVEO is a fixed-dose combination of aztreonam (a monobactam antibiotic) and avibactam (a beta-lactamase inhibitor) administered intravenously for complicated intra-abdominal infections (cIAI) caused by susceptible gram-negative bacteria. The drug works by protecting aztreonam from degradation by bacterial beta-lactamases, restoring its bactericidal activity against resistant gram-negative pathogens. It is indicated for patients with limited or no alternative treatment options.
Growth5.6 years to LOE
Early-stage commercial launch with minimal competitive pressure presents opportunity for team building and market development in hospital-based infectious disease settings.
Mechanism of Action
beta Lactamase Inhibitors
Pharmacologic Class:
beta Lactamase Inhibitor
Worked on EMBLAVEO at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.